<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0695">
 <label>138</label>
 <element-citation publication-type="journal" id="ref0690">
  <person-group person-group-type="author">
   <name>
    <surname>Robinson</surname>
    <given-names>J.E.</given-names>
   </name>
   <name>
    <surname>Hastie</surname>
    <given-names>K.M.</given-names>
   </name>
   <name>
    <surname>Cross</surname>
    <given-names>R.W.</given-names>
   </name>
   <name>
    <surname>Yenni</surname>
    <given-names>R.E.</given-names>
   </name>
   <name>
    <surname>Elliott</surname>
    <given-names>D.H.</given-names>
   </name>
   <name>
    <surname>Rouelle</surname>
    <given-names>J.A.</given-names>
   </name>
  </person-group>
  <article-title>Most neutralizing human monoclonal antibodies target novel epitopes requiring both 
   <italic>Lassa virus</italic> glycoprotein subunits
  </article-title>
  <source>Nat Commun</source>
  <volume>7</volume>
  <year>2016</year>
  <fpage>11544</fpage>
  <pub-id pub-id-type="pmid">27161536</pub-id>
 </element-citation>
</ref>
